MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024, at 4:30 pm ET.
马里兰州罗克维尔，2024年5月3日（环球新闻专线）——专注于开发、制造和商业化治疗癌症的创新抗体疗法的生物制药公司MacroGenics, Inc.（纳斯达克股票代码：MGNX）今天宣布，该公司将在2024年5月9日星期四收盘后发布2024年第一季度的财务业绩。MacroGenics将于美国东部时间2024年5月9日星期四下午4点30分主持电话会议，讨论财务业绩和最近的公司进展。
Conference Call Information
电话会议信息
To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm. A recorded replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for 30 days following the call.
要通过电话参加，请提前在此处注册 链接。注册后，所有电话参与者都将收到一封确认电子邮件，详细说明如何加入电话会议，包括拨入号码以及可用于接听电话的唯一密码和注册人ID。本次电话会议的仅限收听的网络直播可在公司网站投资者关系部分的 “活动与演讲” 下观看 http://ir.macrogenics.com/events.cfm。电话会议结束后不久将提供网络直播的录制重播，并在电话会议结束后的30天内在公司网站上存档。
About MacroGenics, Inc.
关于 MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
MacroGenics（以下简称 “公司”）是一家生物制药公司，专注于开发、制造和商业化用于治疗癌症的基于单克隆抗体的创新疗法。该公司主要从其专有的下一代抗体技术平台套件中生成候选产品线，这些平台适用于广泛的治疗领域。MacroGenics的技术平台和蛋白质工程专业知识相结合，使公司能够开发出有前途的候选产品，并与全球制药和生物技术公司进行多项战略合作。欲了解更多信息，请访问公司的网站 wwwmacrogenics.com。MacroGenics 和 MacroGenics 徽标是 MacroGenics, Inc. 的商标或注册商标。
###
###
CONTACTS: Jim Karrels, Senior Vice President, CFO 1-301-251-5172, info@macrogenics.com
联系人：吉姆·卡雷尔斯，高级副总裁，首席财务官1-301-251-5172， info@macrogenics.com
Source: MacroGenics, Inc.
资料来源：MacroGenics, Inc.
译文内容由第三方软件翻译。